TY - JOUR
T1 - PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263
AU - Munari, Enrico
AU - Zamboni, Giuseppe
AU - Lunardi, Gianluigi
AU - Marconi, Marcella
AU - Sommaggio, Marco
AU - Brunelli, Matteo
AU - Martignoni, Guido
AU - Netto, George J.
AU - Hoque, Mohammad O.
AU - Moretta, Francesca
AU - Mingari, Maria Cristina
AU - Pegoraro, Maria Cristina
AU - Mariotti, Francesca Romana
AU - Vacca, Paola
AU - Moretta, Lorenzo
AU - Bogina, Giuseppe
N1 - Funding Information:
This work was partially supported by Associazione Italiana Ricerca sul Cancro (AIRC) [5x1000 #21147 to L.M.].
Publisher Copyright:
©Munari et al.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - We assessed the concordance, in terms of PD-L1 expression, between primary and metastatic non-small cell lung carcinoma (NSCLC) of different histotypes using validated SP263 clone. A few samples of local recurrences have also been analyzed. Whole sections of consecutive cases of primary NSCLC and paired relapses undergone surgical resection have been stained with PD-L1 clone SP263; for scoring purposes, a three-tiered system was applied using the following thresholds: <1%, 1-49% and ≥50%. Eighty-four cases of paired primary and relapsed tumors from 83 patients were analyzed, including 75 metastases and 9 local recurrences. Regarding metastases, when considering a cutoff of 1%, discrepancy in PD-L1 expression occurred in 9/75 (12%) paired samples (kappa value = 0.75); at 50% cutoff, discrepancy in PD-L1 expression was detected in 7/75 (9.3%) of paired samples (kappa value = 0.61). Regarding recurrences, at 1% cutoff, the discrepancy in PD-L1 expression was seen in 3/9 (33%) paired samples and in all cases there was a gained PD-L1 expression; at 50% cutoff, 1/9 (11%) paired samples showed gained PD-L1 expression. Our data provide important information regarding the concordance between primary and relapsed NSCLC and the degree of reliability of metastatic sites in terms of PD-L1 expression evaluation.
AB - We assessed the concordance, in terms of PD-L1 expression, between primary and metastatic non-small cell lung carcinoma (NSCLC) of different histotypes using validated SP263 clone. A few samples of local recurrences have also been analyzed. Whole sections of consecutive cases of primary NSCLC and paired relapses undergone surgical resection have been stained with PD-L1 clone SP263; for scoring purposes, a three-tiered system was applied using the following thresholds: <1%, 1-49% and ≥50%. Eighty-four cases of paired primary and relapsed tumors from 83 patients were analyzed, including 75 metastases and 9 local recurrences. Regarding metastases, when considering a cutoff of 1%, discrepancy in PD-L1 expression occurred in 9/75 (12%) paired samples (kappa value = 0.75); at 50% cutoff, discrepancy in PD-L1 expression was detected in 7/75 (9.3%) of paired samples (kappa value = 0.61). Regarding recurrences, at 1% cutoff, the discrepancy in PD-L1 expression was seen in 3/9 (33%) paired samples and in all cases there was a gained PD-L1 expression; at 50% cutoff, 1/9 (11%) paired samples showed gained PD-L1 expression. Our data provide important information regarding the concordance between primary and relapsed NSCLC and the degree of reliability of metastatic sites in terms of PD-L1 expression evaluation.
KW - Cancer
KW - Heterogeneity
KW - Lung
KW - Metastases
KW - PD-L1
UR - http://www.scopus.com/inward/record.url?scp=85049877515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049877515&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.25770
DO - 10.18632/oncotarget.25770
M3 - Article
C2 - 30101000
AN - SCOPUS:85049877515
SN - 1949-2553
VL - 9
SP - 30465
EP - 30471
JO - Oncotarget
JF - Oncotarget
IS - 54
ER -